MedTrace Logo

Retroprospective Real Life Observatory of Eribulin

NCT02393287 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 753

Last updated 2019-05-09

No results posted yet for this study

Summary

The objective of this observatory is to evaluate the effecacy of Eribulin in patients with metastatic breast cancer on a recent prescription period.

Part of the data collection will be retrospective and the other part will be prospective for patients started treatment by Eribulin between November 2014 and September 2015. It will allow a better assessment on the safety profile of this drug.

Conditions

Interventions

OTHER

Eribulin (ReProLine)

this is an observational trial ; there is no intervention

Sponsors & Collaborators

  • Institut Cancerologie de l'Ouest

    lead OTHER

Principal Investigators

  • Anne PATSOURIS, MD · Institut de Cancerologie de l'Ouest

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-09-30
Completion
2017-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02393287 on ClinicalTrials.gov